INPP5D

Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 · Q92835 · INPP5D on Sugi Atlas →

3,896 patent compounds predicted against INPP5D, 3,267 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1163246	0.98	2/20
SCHEMBL1163570	0.98	2/20
SCHEMBL1163573	0.98	2/20
SCHEMBL1163654	0.98	2/20
SCHEMBL1881196	0.98	2/20
SCHEMBL2712182	0.98	2/20
SCHEMBL1937432	0.59	2/20
SCHEMBL133391	0.47	2/20
SCHEMBL4018554	0.78	1/20
SCHEMBL4018557	0.78	1/20
Epicoprosterol (SCHEMBL28409)	0.74	1/20
Coprostanol (SCHEMBL28410)	0.74	1/20
Epicoprosterol (SCHEMBL133951)	0.74	1/20
Epicoprosterol (SCHEMBL158868)	0.74	1/20
Epidihydrocholesterin (SCHEMBL776234)	0.74	1/20
Epicoprosterol (SCHEMBL875251)	0.74	1/20
Epicoprosterol (SCHEMBL883702)	0.74	1/20
Epicoprosterol (SCHEMBL2608072)	0.74	1/20
Epicoprosterol (SCHEMBL2721573)	0.74	1/20
Epicoprosterol (SCHEMBL3462802)	0.74	1/20

Clinical trials — most relevant to INPP5D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Pamidronate to Treat Osteogenesis Imperfecta in Children	PHASE3	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Plaque Calcium Characterization and Ruptured Plaques	nan	UNKNOWN
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Molecular Markers of Human Sperm Function	nan	WITHDRAWN
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
Effect of Short-Term Exercise Training on ATP Synthesis in Relatives of Type 2 Diabetic Humans	nan	COMPLETED
Studying Phosphorus Metabolism	nan	COMPLETED
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders	nan	COMPLETED
Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome	nan	COMPLETED
Planetary Habitat Simulation: Bone Metabolism Studies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a INPP5D binder may also engage these)

Protein	Name	Similarity
P97573	—	1.000	P97573 →
Q2I6J1	—	1.000	Q2I6J1 →
Q6P4S2	—	0.998	Q6P4S2 →
Q9ES52	—	0.994	Q9ES52 →
Q6P549	—	0.993	Q6P549 →
INPPL1	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2	0.993	landscape →
A0A8I3NFE2	—	0.992	A0A8I3NFE2 →
Q2I6J0	—	0.990	Q2I6J0 →
Q5F479	—	0.987	Q5F479 →
Q9WVR3	—	0.986	Q9WVR3 →
Q60760	—	0.985	Q60760 →
Q8N4X5	—	0.985	Q8N4X5 →
PIK3C2B	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta	0.985	landscape →
F1SRY5	—	0.985	F1SRY5 →
O15259	—	0.984	O15259 →
Q15052	—	0.984	Q15052 →
Q17R10	—	0.983	Q17R10 →
Q8K4I3	—	0.983	Q8K4I3 →
Q8N5R6	—	0.983	Q8N5R6 →
Q9D684	—	0.983	Q9D684 →
Q8BW70	—	0.983	Q8BW70 →
Q9ULM0	—	0.982	Q9ULM0 →
E9PUQ8	—	0.982	E9PUQ8 →
Q9ES28	—	0.982	Q9ES28 →
Q8C0R0	—	0.982	Q8C0R0 →
PIK3C2G	Phosphatidylinositol 3-kinase C2 domain-containing subunit gamma	0.982	landscape →
P0CI65	—	0.982	P0CI65 →
Q3UJB9	—	0.981	Q3UJB9 →
Q812E4	—	0.981	Q812E4 →
D4A7V9	—	0.981	D4A7V9 →